https://biocc.eeAvaleht | BioCC OÜBioCC tegeleb teadus- ja arendustööga kogu toiduahela ulatuses – alates loomaaretusest ja -söödast kuni kliiniliste katsete ja tervistedendavate toodete väljatöötamiseni. BioCC pakub nii mikrobioloogilisi- kui ka tootearendusteenuseid. Söödalisandite, toiduainete ja toidulisandite loomisel rakendatakse maailmatasemel innovaatilisi biotehnoloogilisi lahendusi.
Name
NORDWISE BioTech OÜ
Registry code
14877534
VAT number
EE102244599
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
30.12.2019 (4)
Financial year
01.01-31.12
Capital
100 000.00 €
Activity
72111 - Research and experimental development on biotechnology
127 238 €
-48 646 €
-38%
1 096 €
(estimate is approximate)
2 732 273 €
2
Submitted
No tax arrears
-2%
-2%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| BioCC OÜ 11077336 | 100% - 100 000.00 EUR | - | - | Founder |
| Ene Tammsaar 03.11.1954 (70) | - | Board member | - | |
| Ülle Jaakma 01.10.1957 (67) | - | - | Indirect ownership | |
| Meeli Lindsaar 11.02.1978 (46) | - | - | - | Board member |
| Jaanus Murakas 25.02.1968 (56) | - | - | - | Board member |
| Meelis Ots 10.08.1970 (54) | - | - | - | Board member |
| Pärt Peterson 18.04.1966 (58) | - | - | - | Board member |
| Tanel-Taavi Bulitko 12.01.1973 (51) | - | - | - | Board member |
| Üllas Jaaska 23.12.1954 (69) | - | - | - | Board member |
| 2020 29.06.2021 | 2021 16.06.2022 | 2022 12.06.2023 | 2023 29.05.2024 | |
|---|---|---|---|---|
| Total Revenue | 53 822 € | 148 201 € | 163 938 € | 127 238 € |
| Net profit (loss) for the period | -42 508 € | -85 831 € | -48 742 € | -48 646 € |
| Profit Margin | -79% | -58% | -30% | -38% |
| Current Assets | 13 281 € | 33 181 € | 83 447 € | 76 206 € |
| Fixed Assets | 2 913 630 € | 2 869 260 € | 2 824 890 € | 2 780 520 € |
| Total Assets | 2 926 911 € | 2 902 441 € | 2 908 337 € | 2 856 726 € |
| Current Liabilities | 11 419 € | 72 780 € | 127 418 € | 124 453 € |
| Non Current Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Share Capital | - | - | - | - |
| Equity | 2 915 492 € | 2 829 661 € | 2 780 919 € | 2 732 273 € |
| Employees | 1 | 2 | 2 | 2 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 49 761.47 € | 6 138.74 € | 4 757.19 € | 3 |
| 2023 Q4 | 32 621.03 € | 6 703.52 € | 3 270.32 € | 3 |
| 2023 Q3 | 18 492.96 € | 6 535.24 € | 4 098.13 € | 3 |
| 2023 Q2 | 61 360.39 € | 6 697.81 € | 2 769.07 € | 3 |
| 2023 Q1 | 32 626.5 € | 5 503.04 € | 2 526.81 € | 2 |
| 2022 Q4 | 36 405.86 € | 11 676.76 € | 6 298.96 € | 4 |
| 2022 Q3 | 26 355.42 € | 10 563.98 € | 7 522.66 € | 3 |
| 2022 Q2 | 25 111.16 € | 7 711.5 € | 6 640.8 € | 4 |
| 2022 Q1 | 75 695.29 € | 12 854.78 € | 6 594.33 € | 4 |
| 2021 Q4 | 29 981.57 € | 8 705.06 € | 6 192.14 € | 4 |
| 2021 Q3 | 18 426.25 € | 8 514.78 € | 6 718.44 € | 4 |
| 2021 Q2 | 42 343.16 € | 8 418.13 € | 4 788.56 € | 4 |
| 2021 Q1 | 22 298.28 € | 3 591.26 € | 3 695.15 € | 3 |
| 2020 Q4 | 30 973.92 € | 7 181.27 € | 2 179.42 € | 3 |
| 2020 Q3 | 4 844.81 € | 764.98 € | 611.94 € | 2 |
| 2020 Q2 | 3 060.24 € | 609.11 € | - | - |
| 2020 Q1 | - | - | - | - |
